Arterioectatic Spinal Angiopathy of Childhood: Clinical, Imaging, Laboratory, Histologic, and Genetic Description of a Novel CNS Vascular Pathology

References

1. 1.↵
   1. Rodesch G,
   2. Hurth M,
   3. Alvarez H, et al

   . Classification of spinal cord arteriovenous shunts: proposal for a reappraisal–the Bicêtre experience with 155 consecutive patients treated between 1981 and 1999. Neurosurgery 2002;51:374–79; discussion 79–80 doi:10.1227/00006123-200208000-00013 pmid:12182775

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Consoli A,
   2. Smajda S,
   3. Trenkler J, et al

   . Intradural spinal cord arteriovenous shunts in the pediatric population: natural history, endovascular management, and follow-up. Childs Nerv Syst 2019;35:945–55 doi:10.1007/s00381-019-04108-0 pmid:30843101

   CrossRefPubMed
3. 3.↵
   1. Cullen S,
   2. Alvarez H,
   3. Rodesch G, et al

   . Spinal arteriovenous shunts presenting before 2 years of age: analysis of 13 cases. Childs Nerv Syst 2006;22:1103–10 doi:10.1007/s00381-006-0075-x pmid:16586138

   CrossRefPubMed
4. 4.↵
   1. Rodesch G,
   2. Hurth M,
   3. Alvarez H, et al

   . Spinal cord intradural arteriovenous fistulae: anatomic, clinical, and therapeutic considerations in a series of 32 consecutive patients seen between 1981 and 2000 with emphasis on endovascular therapy. Neurosurgery 2005;57:973–83; discussion 73–83 doi:10.1227/01.neu.0000181314.94000.cd pmid:16284566

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Parikh S,
   2. Saneto R,
   3. Falk MJ, et al

   . A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009;11:414–30 doi:10.1007/s11940-009-0046-0 pmid:19891905

   CrossRefPubMed
6. 6.↵
   1. Spetzler RF,
   2. Detwiler PW,
   3. Riina HA, et al

   . Modified classification of spinal cord vascular lesions. J Neurosurg 2002;96:145–56 doi:10.3171/spi.2002.96.2.0145 pmid:12450276

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Abruzzo TA,
   2. Kurosawa Y,
   3. Choutka O, et al

   . Genetic determinants of cerebral arterial adaptation to flow-loading. Curr Neurovasc Res 2018;15:175–85 doi:10.2174/1567202615666180712150143 pmid:29998805

   CrossRefPubMed
8. 8.↵
   1. Merry GS,
   2. Appleton DB

   . Spinal arterial malformation in a child with hereditary hemorrhagic telangiectasia: case report. J Neurosurg 1976;44:613–16 doi:10.3171/jns.1976.44.5.0613 pmid:1262922

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Niino M,
   2. Isu T,
   3. Tashiro K

   . Nonhemorrhagic venous infarction of the spinal cord without spinal vascular malformation. J Neurol 1999;246:852–54 doi:10.1007/s004150050470 pmid:10525990

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Viamonte M,
    2. Tuna I,
    3. Rees J

    . Dilated cerebral arteriopathy in classical Pompe disease: a novel finding. Pediatr Neurol 2020;108:117–20 doi:10.1016/j.pediatrneurol.2020.02.006 pmid:32248988

    CrossRefPubMed
11. 11.↵
    1. Brion S,
    2. Netsky MG,
    3. Zimmerman HM

    . Vascular malformations of the spinal cord. AMA Arch Neurol Psychiatry 1952;68:339–61 doi:10.1001/archneurpsyc.1952.02320210049006 pmid:14952072

    CrossRefPubMed
12. 12.↵
    1. Wyburn-Mason R

    . The Vascular Abnormalities and Tumors of the Spinal Cord and Its Membranes. Henry Kimpton; 1943
13. 13.↵
    1. Pearl M,
    2. Gailloud P

    . Spinal vascular malformations in children. J Stroke Cerebrovasc Dis 2017;26:915 doi:10.1016/j.jstrokecerebrovasdis.2017.01.026 pmid:28242248

    CrossRefPubMed
14. 14.↵
    1. Eckart Sorte D,
    2. Obrzut M,
    3. Wyse E, et al

    . Normal venous phase documented during angiography in patients with spinal vascular malformations: incidence and clinical implications. AJNR Am J Neuroradiol 2016;37:565–71 doi:10.3174/ajnr.A4601 pmid:26611990

    Abstract/FREE Full Text
15. 15.↵
    1. Lasjaunias P,
    2. TerBrugge KG,
    3. Berenstein A

    1. Lasjaunias P,
    2. TerBrugge KG,
    3. Berenstein A

    . Spinal cord arteriovenous malformations. In: Lasjaunias P, TerBrugge KG, Berenstein A. Surgical Neuroangiography. 2nd ed. Springer Berlin; 1987:721–66
16. 16.↵
    1. Rahman S

    . Mitochondrial disease in children. J Intern Med 2020;287:609–33 doi:10.1111/joim.13054 pmid:32176382

    CrossRefPubMed
17. 17.↵
    1. Finsterer J,
    2. Zarrouk-Mahjoub S,
    3. Daruich A

    . The eye on mitochondrial disorders. J Child Neurol 2016;31:652–62 doi:10.1177/0883073815599263 pmid:26275973

    CrossRefPubMed
18. 18.↵
    1. Tabarki B,
    2. Hakami W,
    3. Alkhuraish N, et al

    . Spinal cord involvement in pediatric-onset metabolic disorders with mendelian and mitochondrial inheritance. Front Pediatr 2020;8:599861 doi:10.3389/fped.2020.599861 pmid:33520891

    CrossRefPubMed
19. 19.↵
    1. Alves CA,
    2. Goldstein A,
    3. Teixeira SR, et al

    . Involvement of the spinal cord in primary mitochondrial disorders: a neuroimaging mimicker of inflammation and ischemia in children. AJNR Am J Neuroradiol Neuroradiol 2021;42:389–96 doi:10.3174/ajnr.A6910 pmid:33384291

    CrossRefPubMed
20. 20.↵
    1. Lightowlers RN,
    2. Chrzanowska-Lightowlers ZM,
    3. Russell OM

    . Mitochondrial transplantation-a possible therapeutic for mitochondrial dysfunction? Mitochondrial transfer is a potential cure for many diseases but proof of efficacy and safety is still lacking. EMBO Rep 2020;21:e50964 doi:10.15252/embr.202050964 pmid:32852136

    CrossRefPubMed
21. 21.↵
    1. Senyilmaz D,
    2. Virtue S,
    3. Xu X, et al

    . Regulation of mitochondrial morphology and function by stearoylation of TFR1. Nature 2015;525:124–28 doi:10.1038/nature14601 pmid:26214738

    CrossRefPubMed
22. 22.↵
    1. Okuno K,
    2. Naito Y,
    3. Yasumura S, et al

    . Haploinsufficiency of transferrin receptor 1 impairs angiogenesis with reduced mitochondrial complex I in mice with limb ischemia. Sci Rep 2019;9:13658 doi:10.1038/s41598-019-49983-4 pmid:31541184

    CrossRefPubMed
23. 23.↵
    1. Conway AJ,
    2. Brown FC,
    3. Rank G, et al

    . Characterization of Tfrc-mutant mice with microcytic phenotypes. Blood Adv 2018;2:1914–22 doi:10.1182/bloodadvances.2018018820 pmid:30093529

    Abstract/FREE Full Text
24. 24.↵
    1. Wussuki-Lior O,
    2. Abu-Horowitz A,
    3. Netzer I, et al

    . Hematologic biomarkers in childhood cataracts. Mol Vis 2011 17:1011–15 pmid:21541272

    PubMed
25. 25.↵
    1. Aljohani AH,
    2. Al-Mousa H,
    3. Arnaout R, et al

    . Clinical and immunological characterization of combined immunodeficiency due to TFRC mutation in eight patients. J Clin Immunol 2020;40:1103–10 doi:10.1007/s10875-020-00851-1 pmid:32851577

    CrossRefPubMed
26. 26.↵
    1. Jabara HH,
    2. Boyden SE,
    3. Chou J, et al

    . A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet 2016;48:74–78 doi:10.1038/ng.3465 pmid:26642240

    CrossRefPubMed
27. 27.↵
    1. Adam MP,
    2. Mirzaa GM,
    3. Pagon R

    1. Chinnery PF

    . Primary mitochondrial disorders overview. In: Adam MP, Mirzaa GM, Pagon R eds. GeneReviews June 8, 2000
28. 28.↵
    1. Koenig MK

    . Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol 2008;38:305–13 doi:10.1016/j.pediatrneurol.2007.12.001 pmid:18410845

    CrossRefPubMed
29. 29.↵
    1. Zeviani M,
    2. Di Donato S

    . Mitochondrial disorders. Brain 2004;127:2153–72 pmid:15358637

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Finsterer J,
    2. Zarrouk-Mahjoub S

    . Mitochondrial vasculopathy. World J Cardiol 2016;8:333–39 doi:10.4330/wjc.v8.i5.333 pmid:27231520

    CrossRefPubMed
31. 31.↵
    1. Finsterer J,
    2. Mahjoub SZ

    . Primary mitochondrial arteriopathy. Nutr Metab Cardiovasc Dis 2012;22:393–99 doi:10.1016/j.numecd.2012.01.002 pmid:22520486

    CrossRefPubMed
32. 32.↵
    1. Finsterer J

    . Dilative arteriopathy in metabolic myopathies, particularly Pompe’s disease. Acta Neurol Belg 2012;112:15–18 doi:10.1007/s13760-012-0009-1 pmid:22427284

    CrossRefPubMed
33. 33.↵
    1. Finsterer J,
    2. Bastovansky A

    . Dilative arteriopathy and leucencephalopathy as manifestations of a neurometabolic disease. Open Neurol J 2015;9:28–31 doi:10.2174/1874205X01509010028 pmid:26191091

    CrossRefPubMed
34. 34.↵
    1. Naidu S,
    2. Bibat G,
    3. Lin D, et al

    . Progressive cavitating leukoencephalopathy: a novel childhood disease. Ann Neurol 2005;58:929–38 doi:10.1002/ana.20671 pmid:16315274

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Thajeb P,
    2. Dai D,
    3. Chiang MF, et al

    . Genotype-phenotype correlation of maternally inherited disorders due to mutations in mitochondrial DNA. Taiwan J Obstet Gynecol 2006;45:201–07 doi:10.1016/S1028-4559(09)60225-4 pmid:17175464

    CrossRefPubMed
36. 36.↵
    1. Barreras P,
    2. Heck D,
    3. Greenberg B, et al

    . Analysis of 30 spinal angiograms falsely reported as normal in 18 patients with subsequently documented spinal vascular malformations. AJNR Am J Neuroradiol 2017;38:1814–19 doi:10.3174/ajnr.A5275 pmid:28729296

    Abstract/FREE Full Text
37. 37.↵
    1. Gilbertson JR,
    2. Miller GM,
    3. Goldman MS, et al

    . Spinal dural arteriovenous fistulas: MR and myelographic findings. AJNR Am J Neuroradiol 1995;16:2049–57 pmid:8585493

    PubMedWeb of Science
38. 38.↵
    1. Stellingwerff MD,
    2. Figuccia S,
    3. Bellacchio E, et al

    . LBSL: case series and DARS2 variant analysis in early severe forms with unexpected presentations. Neurol Genet 2021;7:e559 doi:10.1212/NXG.0000000000000559 pmid:33977142

    Abstract/FREE Full Text
39. 39.↵
    1. Eom S,
    2. Lee HN,
    3. Lee S, et al

    . Cause of death in children with mitochondrial diseases. Pediatr Neurol 2017;66:82–88 doi:10.1016/j.pediatrneurol.2016.10.006 pmid:27843091

    CrossRefPubMed
40. 40.↵
    1. Brunetti-Pierri N,
    2. Pignatelli R,
    3. Fouladi N, et al

    . Dilation of the aortic root in mitochondrial disease patients. Mol Genet Metab 2011;103:167–70 doi:10.1016/j.ymgme.2011.02.007 pmid:21406331

    CrossRefPubMed
41. 41.↵
    1. Ganetzky RD,
    2. Falk MJ

    . 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab 2018;123:301–08 doi:10.1016/j.ymgme.2018.01.010 pmid:29428506

    CrossRefPubMed
42. 42.↵
    1. Koenig MK,
    2. Emrick L,
    3. Karaa A, et al

    . Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. JAMA Neurol 2016;73:591–94 doi:10.1001/jamaneurol.2015.5072 pmid:26954033

    CrossRefPubMed
43. 43.↵
    1. Gimenes AC,
    2. Bravo DM,
    3. Napolis LM, et al

    . Effect of L-carnitine on exercise performance in patients with mitochondrial myopathy. Braz J Med Biol Res 2015;48:354–62 doi:10.1590/1414-431X20143467 pmid:25714882

    CrossRefPubMed
44. 44.↵
    1. Murphy PA,
    2. Kim TN,
    3. Huang L, et al

    . Constitutively active Notch4 receptor elicits brain arteriovenous malformations through enlargement of capillary-like vessels. Proc Natl Acad Sci U S A 2014;111:18007–12 doi:10.1073/pnas.1415316111 pmid:25468970

    Abstract/FREE Full Text
45. 45.↵
    1. Lasjaunias PL,
    2. Landrieu P,
    3. Rodesch G, et al

    . Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral AVMs. Stroke 2008;39:878–85 doi:10.1161/STROKEAHA.107.493080 pmid:18239181

    Abstract/FREE Full Text